• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Eliminating Medication Copayments for Low-income Older Adults at High Cardiovascular Risk: A Randomized Controlled Trial
Conclusions: In low-income adults at high cardiovascular risk, eliminating copayments (average $35 a month) did not improve clinical outcomes or reduce healthcare costs, despite a modest improvement in adherence to medications.PMID:36871215 | DOI:10.1161/CIRCULATIONAHA.123.064188
Source: Circulation - March 5, 2023 Category: Cardiology Authors: David J T Campbell Chad Mitchell Brenda R Hemmelgarn Marcello Tonelli Peter Faris Jianguo Zhang Ross T Tsuyuki Jane Fletcher Flora Au Scott Klarenbach Derek V Exner Braden J Manns Interdisciplinary Chronic Disease Collaboration Source Type: research

Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab
CONCLUSIONS: In patients with recent acute coronary syndrome and elevated atherogenic lipoproteins, MACEs increased across baseline apoB strata. Alirocumab reduced MACEs across all strata of baseline apoB, with larger absolute reductions in patients with higher baseline levels. Lower achieved apoB was associated with lower risk of MACEs, even after accounting for achieved low-density lipoprotein cholesterol or non-high-density lipoprotein cholesterol, indicating that apoB provides incremental information. Achievement of an apoB level ≤35 mg/dL may reduce lipoprotein-attributable residual risk after acute coronary syndrom...
Source: Circulation - June 30, 2022 Category: Cardiology Authors: Emil Hagstr öm P Gabriel Steg Michael Szarek Deepak L Bhatt Vera A Bittner Nicolas Danchin Rafael Diaz Shaun G Goodman Robert A Harrington J Wouter Jukema Evangelos Liberopoulos Nikolaus Marx Jennifer McGinniss Garen Manvelian Robert Pordy Michel Scemama Source Type: research

Adverse Pregnancy Outcomes and Cardiovascular Disease Risk: Unique Opportunities for Cardiovascular Disease Prevention in Women: A Scientific Statement From the American Heart Association
Circulation. 2021 Mar 29:CIR0000000000000961. doi: 10.1161/CIR.0000000000000961. Online ahead of print.ABSTRACTThis statement summarizes evidence that adverse pregnancy outcomes (APOs) such as hypertensive disorders of pregnancy, preterm delivery, gestational diabetes, small-for-gestational-age delivery, placental abruption, and pregnancy loss increase a woman's risk of developing cardiovascular disease (CVD) risk factors and of developing subsequent CVD (including fatal and nonfatal coronary heart disease, stroke, peripheral vascular disease, and heart failure). This statement highlights the importance of recognizing APOs...
Source: Circulation - March 29, 2021 Category: Cardiology Authors: Nisha I Parikh Juan M Gonzalez Cheryl A M Anderson Suzanne E Judd Kathryn M Rexrode Mark A Hlatky Erica P Gunderson Jennifer J Stuart Dhananjay Vaidya American Heart Association Council on Epidemiology and Prevention; Council on Arteriosclerosis, Thrombos Source Type: research

Clinical Efficacy and Safety of Alirocumab after Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol: A Propensity Score-Matched Analysis of the ODYSSEY OUTCOMES Trial.
Conclusions: After accounting for differences in baseline characteristics and adherence, patients treated with alirocumab who achieved LDL-C levels <25 mg/dL did not appear to derive further reduction in the risk of MACE compared to those who achieved LDL-C levels of 25-50 mg/dL. Clinical Trial Registration: URL: https://www.clinicaltrials.gov Unique identifier: NCT01663402. PMID: 33438437 [PubMed - as supplied by publisher]
Source: Circulation - January 13, 2021 Category: Cardiology Authors: Schwartz GG, Steg PG, Bhatt DL, Bittner VA, Diaz R, Goodman SG, Jukema JW, Kim YU, Li QH, Manvelian G, Pordy R, Sourdille T, White HD, Szarek M, ODYSSEY OUTCOMES Committees and Investigators Tags: Circulation Source Type: research

Biomarkers of Dietary Omega-6 Fatty Acids and Incident Cardiovascular Disease and Mortality: An Individual-Level Pooled Analysis of 30 Cohort Studies.
CONCLUSIONS: In pooled global analyses, higher in vivo circulating and tissue levels of LA and possibly AA were associated with lower risk of major cardiovascular events. These results support a favorable role for LA in CVD prevention. PMID: 30971107 [PubMed - as supplied by publisher]
Source: Circulation - April 10, 2019 Category: Cardiology Authors: Marklund M, Wu JHY, Imamura F, Del Gobbo LC, Fretts A, de Goede J, Shi P, Tintle N, Wennberg M, Aslibekyan S, Chen TA, de Oliveira Otto MC, Hirakawa Y, Eriksen HH, Kröger J, Laguzzi F, Lankinen M, Murphy RA, Prem K, Samieri C, Virtanen J, Wood AC, Wong K Tags: Circulation Source Type: research

Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the Treating to New Targets (TNT) Trial.
Conclusions -The present post-hoc analysis from TNT shows that increased TRL-C levels associate an increased cardiovascular risk and provides evidence for the cardiovascular benefit of lipid-lowering with statins among CHD patients with high TRL-C. Clinical Trial Registration -URL: https://clinicaltrials.gov Unique Identifier: NCT00327691. PMID: 29618599 [PubMed - as supplied by publisher]
Source: Circulation - April 4, 2018 Category: Cardiology Authors: Vallejo-Vaz AJ, Fayyad R, Boekholdt SM, Hovingh GK, Kastelein JJ, Melamed S, Barter P, Waters DD, Ray KK Tags: Circulation Source Type: research

Evaluating the Impact and Cost-Effectiveness of Statin Use Guidelines for Primary Prevention of Coronary Heart Disease and Stroke.
Conclusions -At a population level, the ACC-AHA guideline for expanded statin use for primary prevention is projected to treat more people, save more lives, and cost less compared with ATP III, in both men and women. Whether individuals benefit from long-term statin use for primary prevention depends more on the disutility associated with pill burden than their degree of cardiovascular risk. PMID: 28687710 [PubMed - as supplied by publisher]
Source: Circulation - July 7, 2017 Category: Cardiology Authors: Heller DJ, Coxson PG, Penko J, Pletcher MJ, Goldman L, Odden MC, Kazi DS, Bibbins-Domingo K Tags: Circulation Source Type: research

Incident Cardiovascular Disease Among Adults with Blood Pressure < 140/90 mm Hg.
Conclusions -While higher BP levels are associated with increased CVD risk, in the modern era, the majority of incident CVD events occur in US adults with SBP/DBP<140/90 mmHg. Although absolute risk and cost-effectiveness should be considered, additional CVD risk reduction measures for adults with SBP/DBP<140/90 mmHg at high risk for CVD may be warranted. PMID: 28634217 [PubMed - as supplied by publisher]
Source: Circulation - June 20, 2017 Category: Cardiology Authors: Tajeu GS, Booth JN, Colantonio LD, Gottesman RF, Howard G, Lackland DT, O'Brien E, Oparil S, Ravenell JE, Safford MM, Seals SR, Shimbo D, Shea S, Spruill TM, Tanner RM, Muntner P Tags: Circulation Source Type: research

Association of Serum Lipids and Coronary Heart Disease in Contemporary Observational Studies.
CONCLUSIONS: -The association between lipids and CHD in contemporary studies may be attenuated due to preferential use of statins by high risk individuals. PMID: 26659948 [PubMed - as supplied by publisher]
Source: Circulation - December 9, 2015 Category: Cardiology Authors: Colantonio LD, Bittner V, Reynolds K, Levitan EB, Rosenson RS, Banach M, Kent ST, Derose SF, Zhou H, Safford MM, Muntner P Tags: Circulation Source Type: research

Changing Cholesterol Levels and Coronary Heart Disease Risk.
Abstract A report by Colantonio and colleagues in this issue of Circulation describes the relations between serum lipoprotein cholesterol levels and triglycerides with coronary heart disease (CHD) incidence.(1) Their analyses draw upon the experience of three American population samples of adults with 8.9 years of follow up. The first study group is the Reasons for Geographic and Racial Differences in Stroke (REGARDS, National Institutes of Health observational cohort, baseline 2003-2007), the second investigation is the Atherosclerosis Risk in Communities (ARIC, National Heart, Lung and Blood observational cohort...
Source: Circulation - December 9, 2015 Category: Cardiology Authors: Wilson PW Tags: Circulation Source Type: research

Utility of Non-Traditional Risk Markers in Individuals Ineligible for Statin Therapy According to the 2013 ACC/AHA Cholesterol Guidelines.
CONCLUSIONS: -In this generally low-risk population sample, a large proportion of ASCVD events occurred among adults with a 10-yr. cPCE risk <7.5%. We found that the CAC, hsCRP, FH and ABI recommendations by the ACC/AHA cholesterol guidelines (Class IIB) identify small subgroups of asymptomatic population with <7.5% 10 yr. cPCE but with observed ASCVD event rates higher than 7.5% who may warrant statin therapy considerations. PMID: 26224808 [PubMed - as supplied by publisher]
Source: Circulation - July 29, 2015 Category: Cardiology Authors: Yeboah J, Polonsky TS, Young R, McClelland RL, Delaney JC, Dawood F, Blaha MJ, Miedema MD, Sibley CT, Carr JJ, Burke GL, Goff DC, Psaty BM, Greenland P, Herrington DM Tags: Circulation Source Type: research